The new era progress in immunotherapy of glioma

Abstract

Glioma is the most common primary tumor of central nervous system (CNS), about 50% of which is extremely malignant glioblastoma (GBM). GBM is the most common primary malignant brain tumors in adults. Surgery, radiotherapy and chemotherapy (most with temozolomide) are regarded as the conventional treatments, but they failed to significantly prolong the survival of GBM patients. The standard treatment of GBM lacks of specificity, and tumor cells are resistant to radiotherapy or alkylating agents, thus recurrence of GBM is inevitably and the overall prognosis is quite poor. Currently, tumor immunotherapy is emerging and booming, which provides more treating options for GBM. This study, hence, reviews the current status of immunotherapy among the comprehensive treatments of glioma, at the same time indicates the potential targets of immunotherapy, further to update treatment strategies and explain the potential for the resistance of immunotherapy. DOI：10.3969/j.issn.1672⁃6731.2019.11.003

Keywords

• glioma
• immunotherapy
• cancer vaccine
• immunosuppressive agents
• genes, viral
• review